Rating Rationale
July 16, 2019 | Mumbai
Vital Healthcare Private Limited
Long-term rating upgraded to 'CRISIL B+/Stable' ; short-term rating reaffirmed
 
Rating Action
Total Bank Loan Facilities Rated Rs.60 Crore
Long Term Rating CRISIL B+/Stable (Upgraded from 'CRISIL B/Stable')
Short Term Rating CRISIL A4 (Reaffirmed)
1 crore = 10 million
Refer to annexure for Details of Instruments & Bank Facilities
Detailed Rationale

CRISIL has upgraded its ratings on the long term bank loan facilities of Vital Healthcare Private Limited (VHPL) to 'CRISIL B+/Stable' from 'CRISIL B/Stable' while reaffirming its rating on the short term facilities at 'CRISIL A4'.

The upgrade reflects the improvement in VHPL's financial risk profile with improvement in total outside liabilities to adjusted networth (TOLANW) of 0.6 times estimated in fiscal 2019 from 1.1 times in fiscal year 2017. Debt protection metrics has also improved with better profitability margin to estimated 3.5 times in fiscal 2019, from 2.23 times. Expected growth in revenue and profitability should strengthen the firm's financial risk profile and liquidity, in the absence of major capital expenditure, over the medium term.

The ratings continue to reflect large working capital requirements and modest scale of operations amidst intense competition. These rating weaknesses are partially offset by the extensive industry experience of the company's promoters and above average financial risk profile.

Analytical Approach

Unsecured loans of Rs 6.77 crore as on March 2019, extended by the proprietor and family members, have been treated as neither debt nor equity, as these funds are expected to remain in business over the medium term.

Key Rating Drivers & Detailed Description
Weakness:
* Modest scale of operations amidst intense competition:
Modest scale of operations, reflected in revenue of Rs 20.33 crore estimated in fiscal 2019, limits bargaining power with suppliers and customers, in the highly fragmented pharmaceutical formulations industry.
 
* Large working capital requirement:
Operations are working capital intensive, reflected in gross current assets of 400-600 days in the past four fiscal ended March 2019, driven by stretched receivables of 200-300 days due to delayed payments from government agencies, and inventory of 100 days due to customers majorly government agencies provide dispatch schedule for over the year in advance.
 
Strengths:
* Extensive experience in pharmaceutical formulations industry:
The two decade-long experience of the promoter, Mr. Sachin Gandhi, in the pharmaceutical formulations business, and established relationships with major suppliers and customers, will continue to support the business risk profile.
 
* Above average financial risk profile:
Capital structure is marked by low TOLANW of 0.6 time and strong networth of Rs 31.25 crore, estimated, as on March 31, 2019. Debt protection metrics is comfortable with interest cover and net cash accrual to adjusted debt ratios of 3.27 times and 1.24 time, respectively, estimated for fiscal 2019.
Liquidity

VHPL has moderate liquidity marked by expected cash accruals of Rs.2-3 crore per annum in fiscal 2020 and fiscal 2021 respectively and cash and cash equivalents of Rs. 3.78 crore estimated as on March 31, 2019. VHPL also has access to fund based limits of Rs. 4.90 crore, utilized to the tune of 38 per cent on an average over the 12 months ended May 2019. The company has long term repayment obligations around Rs.0.44 crore and 0.08 crore annually in fiscal 2020 and fiscal 2021, respectively. 

Outlook: Stable

CRISIL believes VHPL will maintain the stable business risk profile over the medium term, backed by experience of promoters. The outlook may be revised to 'Positive' if significant and sustainable increase in revenue and margin while working capital cycle improves, leads to better financial risk profile. Conversely, the outlook may be revised to 'Negative' if significant, debt-funded capital expenditure or decline in cash accrual, or stretch in working capital cycle, weakens financial risk profile.

About the Company

Incorporated in 1992, VHPL manufactures and markets pharmaceutical formulations and healthcare products at its manufacturing facility in Nashik (Maharashtra). Mr. Sachin Gandhi is a promoter of the company with around two decades of experience in pharmaceutical formulations industry.

Key Financial Indicators
Particulars Unit 2018 2017
Revenue Rs Cr. 16.88 26.09
Profit After Tax (PAT) Rs Cr. 0.96 1.14
PAT Margin % 5.68 4.35
Adjusted debt/Adjusted networth Times 0.19 0.30
Interest coverage Times 2.49 2.24

Any other information: Not applicable

Note on complexity levels of the rated instrument:
CRISIL complexity levels are assigned to various types of financial instruments. The CRISIL complexity levels are available on www.crisil.com/complexity-levels. Users are advised to refer to the CRISIL complexity levels for instruments that they consider for investment. Users may also call the Customer Service Helpdesk with queries on specific instruments.
Annexure - Details of Instrument(s)
ISIN Name of Instrument Date of Allotment Coupon
Rate (%)
Maturity Date Issue
Size
(Rs.Cr)
Rating Assigned  with Outlook
NA Letter of Credit NA NA NA 5.72 CRISIL A4
NA Term Loan NA NA Mar-2021 2 CRISIL B+/Stable
NA Proposed Long Term Bank Loan Facility NA NA NA 34.78 CRISIL B+/Stable
NA Bank Guarantee NA NA NA 7 CRISIL A4
NA Bill Negotiation NA NA NA 2 CRISIL A4
NA Cash Credit NA NA NA 8.5 CRISIL B+/Stable
Annexure - Rating History for last 3 Years
  Current 2019 (History) 2018  2017  2016  Start of 2016
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Fund-based Bank Facilities  LT/ST  45.28  CRISIL B+/Stable      29-06-18  CRISIL B/Stable  27-03-17  CRISIL B/Stable/ CRISIL A4      CRISIL B/Stable/ CRISIL A4 
Non Fund-based Bank Facilities  LT/ST  14.72  CRISIL A4      29-06-18  CRISIL A4  27-03-17  CRISIL A4      CRISIL A4 
All amounts are in Rs.Cr.
Annexure - Details of various bank facilities
Current facilities Previous facilities
Facility Amount (Rs.Crore) Rating Facility Amount (Rs.Crore) Rating
Bank Guarantee 7 CRISIL A4 Bank Guarantee 7 CRISIL A4
Bill Negotiation 2 CRISIL A4 Bill Negotiation 2 CRISIL A4
Cash Credit 8.5 CRISIL B+/Stable Cash Credit 8.5 CRISIL B/Stable
Letter of Credit 5.72 CRISIL A4 Letter of Credit 5.72 CRISIL A4
Proposed Long Term Bank Loan Facility 34.78 CRISIL B+/Stable Proposed Long Term Bank Loan Facility 34.78 CRISIL B/Stable
Term Loan 2 CRISIL B+/Stable Term Loan 2 CRISIL B/Stable
Total 60 -- Total 60 --
Links to related criteria
CRISILs Approach to Financial Ratios
CRISILs Bank Loan Ratings - process, scale and default recognition
Rating criteria for manufaturing and service sector companies
Rating Criteria for the Pharmaceutical Industry
CRISILs Bank Loan Ratings
CRISILs Criteria for rating short term debt
The Rating Process
Understanding CRISILs Ratings and Rating Scales

For further information contact:
Media Relations
Analytical Contacts
Customer Service Helpdesk
Saman Khan
Media Relations
CRISIL Limited
D: +91 22 3342 3895
B: +91 22 3342 3000
saman.khan@crisil.com

Naireen Ahmed
Media Relations
CRISIL Limited
D: +91 22 3342 1818
B: +91 22 3342 3000
naireen.ahmed@crisil.com

Vinay Rajani
Media Relations
CRISIL Limited
D: +91 22 3342 1835
M: +91 91 676 42913
B: +91 22 3342 3000
vinay.rajani@ext-crisil.com

Rahul Guha
Director - CRISIL Ratings
CRISIL Limited
D:+91 22 4097 8320
rahul.guha@crisil.com


Ankita Gupta
Associate Director - CRISIL Ratings
CRISIL Limited
D:+91 22 4097 8104
ankita.gupta@crisil.com


Prashant Paradhi
Rating Analyst - CRISIL Ratings
CRISIL Limited
B:+91 22 3342 3000
Prashant.Paradhi@crisil.com
Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper / magazine / agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL. However, CRISIL alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites, portals etc.


About CRISIL Limited

CRISIL is a leading agile and innovative, global analytics company driven by its mission of making markets function better. We are India’s foremost provider of ratings, data, research, analytics and solutions. A strong track record of growth, culture of innovation and global footprint sets us apart. We have delivered independent opinions, actionable insights, and efficient solutions to over 1,00,000 customers.
 
We are majority owned by S&P Global Inc., a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.
 
For more information, visit www.crisil.com 


Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK

About CRISIL Ratings
CRISIL Ratings is part of CRISIL Limited (“CRISIL”). We pioneered the concept of credit rating in India in 1987. CRISIL is registered in India as a credit rating agency with the Securities and Exchange Board of India (“SEBI”). With a tradition of independence, analytical rigour and innovation, CRISIL sets the standards in the credit rating business. We rate the entire range of debt instruments, such as, bank loans, certificates of deposit, commercial paper, non-convertible / convertible / partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 24,500 large and mid-scale corporates and financial institutions. CRISIL has also instituted several innovations in India in the rating business, including rating municipal bonds, partially guaranteed instruments and microfinance institutions. We also pioneered a globally unique rating service for Micro, Small and Medium Enterprises (MSMEs) and significantly extended the accessibility to rating services to a wider market. Over 1,10,000 MSMEs have been rated by us.


CRISIL PRIVACY
 
CRISIL respects your privacy. We may use your contact information, such as your name, address, and email id to fulfil your request and service your account and to provide you with additional information from CRISIL.For further information on CRISIL’s privacy policy please visit www.crisil.com.


DISCLAIMER

This disclaimer forms part of and applies to each credit rating report and/or credit rating rationale that we provide (each a “Report”). For the avoidance of doubt, the term “Report” includes the information, ratings and other content forming part of the Report. The Report is intended for the jurisdiction of India only. This Report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the Report is to be construed as CRISIL providing or intending to provide any services in jurisdictions where CRISIL does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this Report does not create a client relationship between CRISIL and the user.

We are not aware that any user intends to rely on the Report or of the manner in which a user intends to use the Report. In preparing our Report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the Report is not intended to and does not constitute an investment advice. The Report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind or otherwise enter into any deal or transaction with the entity to which the Report pertains. The Report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Rating are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold, or sell any securities / instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL assumes no obligation to update its opinions following publication in any form or format although CRISIL may disseminate its opinions and analysis. CRISIL rating contained in the Report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the Report should rely on their own judgment and take their own professional advice before acting on the Report in any way.CRISIL or its associates may have other commercial transactions with the company/entity.

Neither CRISIL nor its affiliates, third party providers, as well as their directors, officers, shareholders, employees or agents (collectively, “CRISIL Parties”) guarantee the accuracy, completeness or adequacy of the Report, and no CRISIL Party shall have any liability for any errors, omissions, or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the Report. EACH CRISIL PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the Report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. CRISIL’s public ratings and analysis as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any) are made available on its web sites, www.crisil.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee – more details about CRISIL ratings are available here: www.crisilratings.com.

CRISIL and its affiliates do not act as a fiduciary. While CRISIL has obtained information from sources it believes to be reliable, CRISIL does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and / or relies in its Reports. CRISIL keeps certain activities of its business units separate from each other in order to preserve the independence and objectivity of the respective activity. As a result, certain business units of CRISIL may have information that is not available to other CRISIL business units. CRISIL has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL has in place a ratings code of conduct and policies for analytical firewalls and for managing conflict of interest. For details please refer to: https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html

CRISIL’s rating criteria are generally available without charge to the public on the CRISIL public web site, www.crisil.com. For latest rating information on any instrument of any company rated by CRISIL you may contact CRISIL RATING DESK at CRISILratingdesk@crisil.com, or at (0091) 1800 267 1301.

This Report should not be reproduced or redistributed to any other person or in any form without a prior written consent of CRISIL.

All rights reserved @ CRISIL